Replaces Prod. #: BML-EI111
Potent and selective orally active inhibitor of thromboxane A2 synthase (ED50=10ng/ml, human platelets).
Product Details
| Alternative Name: | U-63557A, Sodium furegrelate |
| |
| Formula: | C15H10NO3 . Na |
| |
| MW: | 252.2 . 23.0 |
| |
| CAS: | 85666-17-7 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | White to off-white crystalline solid. |
| |
| Solubility: | Soluble in water (15mg/ml), methanol or DMSO. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year when stored at -20°C. Before use, prepare a stock solution by dissolving the product in water. Stock solutions will be stable for at least 1 month if stored at 0°C in an oxygen-free environment. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Angiotensin II constriction of rat vasa recta is partially thromboxane dependent: E.P. Silldorff, et al.; Hypertension
40, 541 (2002),
Abstract;
Multiple dose trial of the thromboxane synthase inhibitor furegrelate in normal subjects: J.S. Mohrland, et al.; Eur. J. Clin. Pharmacol.
38, 485 (1990),
Abstract;
Pharmacokinetics of furegrelate after oral administration to normal humans: D.B. Lakings, et al.; Pharm. Res.
6, 53 (1989),
Abstract;
Thromboxane synthase activity and platelet function after furegrelate administration in man: J.S. Mohrland, et al.; J. Clin. Pharmacol.
29, 53 (1989),
Abstract;
Pharmacology and therapeutic actions of the thromboxane synthetase inhibitor furegrelate: A.M. Lefer; Drugs Future 11, 197 (1986),
Thromboxane A2 synthase inhibitors. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acids: R.A. Johnson, et al.; J. Med. Chem.
29, 1461 (1986),
Abstract;
Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate: R.R. Gorman, et al.; Prostaglandins
26, 325 (1983),
Abstract;
